Is event-driven PrEP dosing for HIV as effective as daily dosing? | Zendy

T. I. Olsen | Zendy; Zachary C Lally-Montgomery | Zendy; Gary Kelsberg | Zendy; Sarah Safranek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is event-driven PrEP dosing for HIV as effective as daily dosing?

Author(s) -

T. I. Olsen,

Zachary C Lally-Montgomery,

Gary Kelsberg,

Sarah Safranek

Publication year - 2021

Publication title -

the journal of family practice

Language(s) - English

Resource type - Journals

eISSN - 1533-7294

DOI - 10.12788/jfp.0207

Subject(s) - medicine , dosing , cohort , prospective cohort study , pre exposure prophylaxis , placebo , randomized controlled trial , human immunodeficiency virus (hiv) , men who have sex with men , family medicine , alternative medicine , syphilis , pathology

PROBABLY, although there are no head-to-head trials comparing the 2 dosing regimens. Event-driven pre-exposure prophylaxis (PrEP) dosing reduces HIV conversion by 86% compared to placebo (strength of recommendation [SOR]: B, large randomized controlled trial [RCT]). Daily PrEP reduces HIV conversion by 44% to 86% (SOR: B, based on open-label RCTs).Event-driven PrEP regimens may be associated with lower adherence when compared with daily PrEP regimens (average of 70% for event-driven PrEP vs average of 92% for daily PrEP) (SOR: B, based on open-label and cohort trials). Event-driven PrEP regimens have lower medication costs, and they are associated with no difference in the rate of sexually transmitted infections (STIs) (SOR: B, based on prospective cohort studies). Patients may prefer them to daily regimens (75% choose event driven PrEP vs 25% choose daily PrEP) (SOR: BB, based on the preponderance of prospective cohort studies with conflicting results).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research